Gut Hormones and Nutritional Status After a Standardized Meal. (GUT-NUT)
torstai 28. toukokuuta 2026 päivittänyt: Medical University of Bialystok
Analysis of Differences in Serum Concentrations of Selected Gut Hormones in Patients With Varying Nutritional Status Following Consumption of a Standardized Meal.
This study evaluated differences in serum concentrations of selected gut hormones (GLP-1, GIP, cholecystokinin, and omentin) among individuals with varying nutritional status following a standardized meal.
A total of 80 adults were enrolled and stratified by BMI. Fasting and postprandial hormone levels were assessed at multiple time points.
Additionally, dietary habits, physical activity, body composition, and resting energy expenditure were evaluated to explore their association with hormonal responses.
Tutkimuksen yleiskatsaus
Yksityiskohtainen kuvaus
Stage I
Participant recruitment
A total of 80 participants (women and men) aged 40-60 years who voluntarily consent to participate in the study will be enrolled:
Control group (G0): 20 participants (10 women, 10 men) with normal body weight - BMI 18.5-24.9 kg/m² Study group I (G1): 20 participants (10 women, 10 men) with overweight - BMI 25.0-29.9 kg/m² Study group II (G2): 20 participants (10 women, 10 men) with class I obesity - BMI 30.0-34.9 kg/m² Study group III (G3): 20 participants (10 women, 10 men) with class II obesity - BMI 35.0-39.9 kg/m²
Assessment of dietary habits, physical activity, and quality of life
Participants will complete a questionnaire-based survey consisting of the following standardized instruments:
- Questionnaire for the Assessment of Dietary Habits and Opinions on Food and Nutrition (QEB Questionnaire developed by the Committee of Human Nutrition Science, Polish Academy of Sciences);
- International Physical Activity Questionnaire (IPAQ);
- Quality of Life Questionnaire (WHOQOL-BREF);
- The Three-Factor Eating Questionnaire (TFEQ-R18);
- "My Eating Habits: Construction and Psychometric Properties" Questionnaire (N. Ogińska-Bulik, L. Putyński);
- The Hunger-Satiety Scale. The questionnaire survey will enable qualitative assessment of participants' dietary habits, physical activity levels, quality of life, and emotional determinants related to food intake.
Quantitative assessment of dietary intake will be performed using a 24-hour dietary recall collected over three days (two weekdays and one weekend day).
- Nutritional Status Assessment Anthropometric measurements including body height and body weight will be obtained using a calibrated scale with a stadiometer. Waist circumference (cm) will be measured midway between the lower rib margin and the iliac crest, while hip circumference (cm) will be measured at the point of maximum gluteal protuberance. Based on these measurements, the following indices will be calculated: BMI, WHR, WHtR, and RFM.
Body composition analysis will also be performed using dual-energy X-ray absorptiometry (DEXA), which utilizes dual-energy X-ray beams. This technique allows assessment of the whole body and individual body segments by dividing body composition into three main compartments: bone mineral content, lean body mass (excluding bone mineral content), and fat mass.
DEXA is considered a valuable tool for body composition assessment in clinical studies, particularly among individuals with overweight and obesity, as it enables more accurate evaluation of body composition and long-term cardiovascular and oncological risk associated with excess body weight.
The method is safe, rapid, and non-invasive due to the very low radiation dose. Radiation exposure during the examination is approximately 0.001 mSv. The examination is performed in the supine position.
Stage II
- Biochemical analyses: assessment of serum GLP-1, GIP, cholecystokinin, and omentin concentrations in the fasting state and following administration of a standardized meal. Blood samples (10 mL) will be collected for the following laboratory tests: complete blood count (CBC), fasting glucose, fasting insulin, lipid profile (total cholesterol, triglycerides [TG], low-density lipoprotein [LDL], and high-density lipoprotein [HDL]), C-reactive protein (CRP), serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), serum uric acid, serum creatinine. Additionally, fasting blood samples (10 mL) will be collected to determine serum concentrations of GLP-1, GIP, cholecystokinin, and omentin.
- Subsequently, participants will receive a standardized normocarbohydrate meal, and additional blood samples (10 mL each) will be collected at 60, 120, 180, and 240 minutes after meal consumption, individually on the same weekday, in order to assess serum concentrations of GLP-1, GIP, cholecystokinin, and omentin at specified time intervals following standardized meal administration. An isocaloric standardized meal (Nutricia, Poland) will be used in the study, consisting of one and half bottle per participant:
Normocarbohydrate formulation (Nutridrink Standard) Composition of the Standardized Meal - Nutridrink Standard Parameter Per 100 mL Energy 240 kcal Carbohydrates 29.6 g
- of energy 49% Sugars 15.5 g Lactose <0.5 g Fat 9.3 g
- of energy 35% Saturated fatty acids 0.86 g Protein 9.6 g
- of energy 16% Dietary fiber 0 g
Stage III
1. Assessment of Resting Metabolic Rate Indirect calorimetry will be performed to accurately measure resting energy expenditure (REE) and determine the energy substrates utilized by the body (carbohydrates and fats).
The examination involves analysis of exhaled air composition (oxygen and carbon dioxide concentrations) using specialized equipment (Q-NRG+, COSMED). Measurements will be conducted using sterile disposable mouthpieces and an oxygen mask. Indirect calorimetry is completely safe, painless, and non-invasive. The examination will be performed once.
The obtained results will be subjected to statistical analysis using Statistica 13.3 software (StatSoft Inc.).
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
80
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
-
Bialystok, Puola, 15-089
- Medical University of Bialystok
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Kuvaus
Inclusion Criteria:
- women and men aged 40-60
Exclusion criteria:
- disorders of carbohydrate metabolism,
- endocrine disorders,
- renal and/or hepatic insufficiency,
- gastrointestinal diseases,
- history of gastroenterological or bariatric surgery,
- pharmacological treatment or use of other agents with known or unknown effects on metabolic and hormonal processes,
- other diseases potentially affecting the obtained results,
- pregnancy and lactation.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Normal Body Weight Group
Participants with normal body weight (BMI: 19-24.9
kg/m2)
|
Participants received 187.5 mL of a ready-to-drink oral nutritional supplement (Nutridrink Protein).
|
|
Kokeellinen: Overweight Group
Participants with overweight (BMI: 25-29.9
kg/m2)
|
Participants received 187.5 mL of a ready-to-drink oral nutritional supplement (Nutridrink Protein).
|
|
Kokeellinen: Obesity I Group
Participants with class I obesity (BMI: 30-34.9
kg/m2)
|
Participants received 187.5 mL of a ready-to-drink oral nutritional supplement (Nutridrink Protein).
|
|
Kokeellinen: Obesity II Group
Participants with class II and class III obesity (BMI > 35 kg/m²)
|
Participants received 187.5 mL of a ready-to-drink oral nutritional supplement (Nutridrink Protein).
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Postprandial hormonal response: GLP-1
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Postprandial changes in serum glucagon-like peptide-1 (GLP-1) (pmol/L).
|
24 months (analyzes were performed throughout the study period).
|
|
Postprandial hormonal response: GIP.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Postprandial changes in serum glucose-dependent insulinotropic polypeptide (GIP) (pg/mL).
|
24 months (analyzes were performed throughout the study period).
|
|
Postprandial hormonal response: cholecystokinin.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Postprandial changes in serum cholecystokinin (pg/mL).
|
24 months (analyzes were performed throughout the study period).
|
|
Postprandial hormonal response: omentin.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Postprandial changes in serum omentin (ng/mL).
|
24 months (analyzes were performed throughout the study period).
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Laboratory parameters: hemoglobin.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Complete blood count assessed from fasting venous blood samples, including hemoglobin (g/dl).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: glucose.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Fasting glucose concentration (mg/dL)
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: insulin.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Fasting insulin concentration (µIU/mL)
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: total cholesterol.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Lipid profile parameters: total cholesterol (mg/dL).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: C-reactive protein concentration.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
C-reactive protein concentration (mg/L)
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: ALT.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Alanine aminotransferase activity (U/L).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: AST.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Aspartate aminotransferase activity (U/L).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: creatinine.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Creatinine concentration (mg/dL).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: uric acid.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Uric acid concentration (mg/dL).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: HDL cholesterol.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Lipid profile parameters: HDL cholesterol.
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: TG.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Lipid profile parameters: triglycerides (mg/dL).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: LDL cholesterol.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Laboratory parameters assessed from fasting blood samples.
Lipid profile parameters: LDL cholesterol (mg/dl).
|
24 months (analyzes were performed throughout the study period).
|
|
Body composition parameters assessed by dual-energy X-ray absorptiometry (DXA) - total fat mass.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Assessment of total fat mass (kg).
|
24 months (analyzes were performed throughout the study period).
|
|
Body composition parameters assessed by dual-energy X-ray absorptiometry (DXA) - visceral adipose tissue.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Assessment of visceral adipose tissue (cm³).
|
24 months (analyzes were performed throughout the study period).
|
|
Body composition parameters assessed by dual-energy X-ray absorptiometry (DXA) - lean body mass.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Assessment of lean body mass (kg).
|
24 months (analyzes were performed throughout the study period).
|
|
Physical activity
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Differences in physical activity levels between participants with normal body weight (BMI 18.5-24.9
kg/m²), overweight (BMI 25.0-29.9
kg/m²), obesity I (BMI 30.0-34.9 kg/m²) and obesity II (≥35 kg/m²) assessed using the IPAQ questionnaire.
|
24 months (analyzes were performed throughout the study period).
|
|
Resting Energy Expenditure
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Resting Energy Expenditure: REE was measured using indirect calorimetry (Q-NRG+, COSMED).
|
24 months (analyzes were performed throughout the study period).
|
|
Dietary habits
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Differences in dietary habits between participants with normal body weight (BMI 18.5-24.9
kg/m²), overweight (BMI 25.0-29.9
kg/m²), obesity I (BMI ≥30.0-34.9
kg/m²) and obesity II (BMI ≥35.0 kg/m²), assessed using standardized questionnaires including the QEB, TFEQ-R18, and the hunger-satiety scale.
|
24 months (analyzes were performed throughout the study period).
|
|
Quality of life of people with normal and excessive body weight.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Quality of life assessed using the World Health Organization Quality of Life questionnaire (WHOQOL-BREF).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: hematocrit.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Complete blood count assessed from fasting venous blood samples, including hematocrit (%).
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: white blood cell count.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Complete blood count assessed from fasting venous blood samples, including white blood cell count ×10^3/µL.
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: red blood cell count.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Complete blood count assessed from fasting venous blood samples, including red blood cell count ×10^6/µL.
|
24 months (analyzes were performed throughout the study period).
|
|
Laboratory parameters: platelet count.
Aikaikkuna: 24 months (analyzes were performed throughout the study period).
|
Complete blood count assessed from fasting venous blood samples, including platelet count ×10^3/µL.
|
24 months (analyzes were performed throughout the study period).
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Päätutkija: Lucyna Ostrowska, Professor, Department of Dietetics and Clinical Nutrition Medical University of Bialystok
Julkaisuja ja hyödyllisiä linkkejä
Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.
Yleiset julkaisut
- Shah M, Franklin B, Adams-Huet B, Mitchell J, Bouza B, Dart L, Phillips M. Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects. Eur J Nutr. 2017 Apr;56(3):1053-1062. doi: 10.1007/s00394-016-1154-8. Epub 2016 Jan 12.
- Dutta B, Tripathy A, Archana PR, Kamath SU. Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome. Diabetol Metab Syndr. 2025 Jul 22;17(1):292. doi: 10.1186/s13098-025-01837-y.
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Tiistai 8. huhtikuuta 2025
Ensisijainen valmistuminen (Todellinen)
Tiistai 14. huhtikuuta 2026
Opintojen valmistuminen (Todellinen)
Tiistai 14. huhtikuuta 2026
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Tiistai 12. toukokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 28. toukokuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Torstai 4. kesäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Torstai 4. kesäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Torstai 28. toukokuuta 2026
Viimeksi vahvistettu
Perjantai 1. toukokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- B.SUB.24.251
- ADN.614.2.2024 (Muu tunniste: Medical University of Bialystok)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
PÄÄTTÄMÄTÖN
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .